Sutro Biopharma (NASDAQ:STRO) Earns Neutral Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Sutro Biopharma (NASDAQ:STRO) in a research report sent to investors on Monday morning, Marketbeat reports. The firm currently has a $2.00 target price on the stock, down from their previous target price of $12.00. HC Wainwright also issued estimates for Sutro Biopharma’s Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.68) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at ($0.13) EPS and FY2029 earnings at ($0.09) EPS.

Other equities analysts have also recently issued reports about the company. Wells Fargo & Company lowered their price objective on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research report on Wednesday, December 11th. Bank of America cut Sutro Biopharma from a “buy” rating to an “underperform” rating and lowered their price target for the company from $11.00 to $1.00 in a report on Friday, March 14th. JMP Securities restated a “market outperform” rating and issued a $17.00 price objective on shares of Sutro Biopharma in a research note on Wednesday, December 11th. Citizens Jmp lowered Sutro Biopharma from an “outperform” rating to a “market perform” rating in a research note on Friday, March 14th. Finally, Wedbush lowered Sutro Biopharma from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $8.00 to $2.00 in a research note on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $6.63.

Sutro Biopharma Stock Performance

STRO stock opened at $0.82 on Monday. The business’s 50 day moving average price is $1.69 and its two-hundred day moving average price is $2.66. Sutro Biopharma has a fifty-two week low of $0.76 and a fifty-two week high of $6.13. The company has a market capitalization of $67.68 million, a price-to-earnings ratio of -0.51 and a beta of 1.22.

Sutro Biopharma (NASDAQ:STRO) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($2.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($2.10). Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%. The company had revenue of $14.00 million during the quarter, compared to the consensus estimate of $10.44 million. During the same period in the prior year, the firm earned ($1.78) earnings per share. Sell-side analysts forecast that Sutro Biopharma will post -2.92 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Sutro Biopharma in the third quarter worth about $1,512,000. Intech Investment Management LLC acquired a new stake in shares of Sutro Biopharma during the third quarter worth $91,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Sutro Biopharma by 16.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 251,995 shares of the company’s stock worth $872,000 after buying an additional 35,167 shares during the period. Bank of Montreal Can acquired a new stake in shares of Sutro Biopharma during the third quarter worth $2,852,000. Finally, FMR LLC lifted its stake in shares of Sutro Biopharma by 24.9% during the third quarter. FMR LLC now owns 189,041 shares of the company’s stock worth $654,000 after buying an additional 37,701 shares during the period. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.